A Phase II Study of Interrupted and Continuous Dose Lenalidomide in Relapsed/refractory Hodgkin Lymphoma

Overview

Journal Haematologica

Specialty Hematology

Date 2023 Sep 14

PMID 37706336

Authors

Todd A Fehniger

Marcus P Watkins

Nkiruka Ezenwajiaku

Fei Wan

David D Hurd

Amanda F Cashen

Kristie A Blum

Andre Goy

Timothy S Fenske

Nina D Wagner-Johnston

Kenneth Carson

Marilyn J Siegel

David Russler-Germain

Stephanie E Schneider

Neha Mehta-Shah

Brad Kahl

Nancy L Bartlett

Affiliations

Soon will be listed here.

References

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani P . Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14):1428-1439. PMC: 6075855. DOI: 10.1200/JCO.2017.76.0793. View

Fehniger T, Larson S, Trinkaus K, Siegel M, Cashen A, Blum K . A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011; 118(19):5119-25. PMC: 3217400. DOI: 10.1182/blood-2011-07-362475. View

Boll B, Plutschow A, Burkle C, Atta J, Pfreundschuh M, Feuring-Buske M . Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. Br J Haematol. 2018; 185(1):42-52. DOI: 10.1111/bjh.15741. View

Moskowitz A, Shah G, Schoder H, Ganesan N, Drill E, Hancock H . Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2021; 39(28):3109-3117. PMC: 9851707. DOI: 10.1200/JCO.21.01056. View

Watkins M, Fanale M, Bartlett N . SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2018; 18(2):81-90. DOI: 10.1016/j.clml.2018.01.001. View

Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G . Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020; 4(1):47-54. PMC: 6960457. DOI: 10.1182/bloodadvances.2019000736. View

Fehniger T, Uy G, Trinkaus K, Nelson A, Demland J, Abboud C . A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2010; 117(6):1828-33. PMC: 3318598. DOI: 10.1182/blood-2010-07-297143. View

Boll B, Borchmann P, Topp M, Hanel M, Reiners K, Engert A . Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2009; 148(3):480-2. DOI: 10.1111/j.1365-2141.2009.07963.x. View

Maly J, Christian B, Zhu X, Wei L, Sexton J, Jaglowski S . A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2017; 17(6):347-353. PMC: 6033275. DOI: 10.1016/j.clml.2017.05.008. View

10.

Connors J, Jurczak W, Straus D, Ansell S, Kim W, Gallamini A . Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2017; 378(4):331-344. PMC: 5819601. DOI: 10.1056/NEJMoa1708984. View

11.

Gribben J, Fowler N, Morschhauser F . Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol. 2015; 33(25):2803-11. PMC: 5320950. DOI: 10.1200/JCO.2014.59.5363. View